Clinical Evidence: What The Trials Show For Both Options
Mounjaro V Wegovy UK: Understanding The Mechanism Differences
The fundamental distinction between Mounjaro and Wegovy lies in their receptor targeting mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormone to promote satiety and reduce appetite. Mounjaro utilises tirzepatide, which acts as a dual agonist targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously. This dual mechanism may influence how each treatment affects hunger signals and glucose metabolism in different individuals. Both prescription-only medicines require clinical assessment to determine suitability for your specific circumstances.
When comparing Mounjaro v Wegovy in the UK, it's essential to understand that both treatments work through the brain's appetite control centres but via different pathways. The GLP-1 component in both medications helps slow gastric emptying, making you feel fuller for longer after meals. However, the additional GIP receptor activation in Mounjaro may provide complementary effects on insulin sensitivity and fat metabolism. Your prescriber at EverydayMeds can evaluate which mechanism aligns better with your metabolic profile and weight management objectives.
Wegovy Pricing Structure And Value In The UK Market
EverydayMeds offers transparent pricing for Wegovy across all dose strengths, starting with the 0.25mg starter dose at £79.99 for weeks 1-4 of treatment. The dose escalation continues with 0.5mg at £94.99 (weeks 5-8), 1mg at £99.99 (weeks 9-12), and 1.7mg at £139.99 (weeks 13-16). The maintenance dose of 2.4mg costs £209.99 for week 17 onwards, reflecting the higher concentration required for sustained weight management. New customers can apply code FIRST40 at checkout, while returning customers use code DOSE25 to access these competitive rates.
Our bundle options provide convenient supply continuity when comparing Mounjaro v Wegovy UK costs. The Intro Duo bundle (0.25mg & 0.5mg) costs £169.99, covering your first 8 weeks of treatment in a single order. For those requiring consistent dosing, our Consistency bundles offer paired supplies: Consistency 0.25mg (×2) at £139.99 or Consistency 2.4mg (×2) at £419.99. The Ultimate Stability Trio provides three months of maintenance supply (2.4mg ×3) for £649.99, ensuring uninterrupted treatment during your weight management journey.
STEP Trial Evidence For Wegovy Weight Loss Results
The STEP clinical trial programme provides robust evidence for Wegovy's efficacy in weight management. In the pivotal STEP 1 trial, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 3 demonstrated even greater results with intensive behavioural therapy, showing around 16% weight reduction when combining Wegovy with comprehensive lifestyle interventions.
Long-term sustainability data from STEP 5 revealed that patients maintained approximately clinically studied weight loss at 2 years of continuous treatment. The SELECT cardiovascular outcomes trial further demonstrated that Wegovy may reduce major cardiovascular events by 20% in adults with established cardiovascular disease. These results represent outcomes in clinical trial settings and individual results may vary based on adherence to prescribed diet and exercise modifications.
How Wegovy Works In Your Body's Weight Control System
Wegovy functions as a GLP-1 receptor agonist, closely mimicking the action of glucagon-like peptide-1, a hormone naturally produced in your intestines after eating. When you inject Wegovy once weekly, it binds to GLP-1 receptors in your brain's hypothalamus, the region responsible for appetite regulation and energy balance. This binding triggers a cascade of signals that reduce hunger sensations and increase feelings of fullness, even with smaller meal portions. The medication also slows gastric emptying, meaning food remains in your stomach longer, prolonging satiety between meals. Additionally, Wegovy may influence food cravings by modulating reward pathways in the brain, potentially reducing the appeal of high-calorie foods that often contribute to weight gain.
Streamlined Ordering Process For UK Patients
Accessing Wegovy through EverydayMeds begins with our comprehensive 3-minute online clinical assessment, designed to evaluate your suitability for this prescription-only medicine. Our qualified prescribers review your medical history, current medications, and weight management goals to ensure Wegovy aligns with your individual health profile. Standard prescriber review takes 3 working days, though express 24-hour review is available for urgent cases. Once approved, your Wegovy pens are dispatched via next-day delivery using specialised cold-chain transportation to maintain the medication's integrity throughout transit. This temperature-controlled process ensures your Wegovy arrives in optimal condition, ready for immediate use or refrigerated storage.
Storage Advantages When Comparing Mounjaro V Wegovy UK Options
Wegovy offers significant storage flexibility compared to Mounjaro, particularly important for UK patients with active lifestyles or frequent travel requirements. While both medications require refrigerated storage at 2-8°C before first use, Wegovy can remain at room temperature (below 30°C) for up to 6 weeks once removed from the fridge. In contrast, Mounjaro maintains stability for only 21 days at room temperature, requiring more careful planning for extended periods away from refrigeration. Both treatments utilise pre-filled pen devices - Wegovy employs the FlexTouch pen system, while Mounjaro uses KwikPen technology. The dose escalation schedule for Wegovy follows a structured 4-week progression through each strength, allowing your body to gradually adapt to increasing doses while minimising potential side effects.
UK-Specific Considerations For Mounjaro V Wegovy Selection
Within the UK healthcare landscape, both Mounjaro and Wegovy have received MHRA approval for weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities. NICE guidance TA875 specifically recommends Wegovy alongside specialist weight management support, reflecting its established evidence base in the NHS framework. The choice between treatments often depends on individual response patterns, with some patients experiencing better appetite control with GLP-1-only targeting (Wegovy) while others may benefit from dual receptor activation (Mounjaro).
Access considerations also differ when comparing Mounjaro v Wegovy UK availability. EverydayMeds maintains consistent stock levels for both treatments through our GPhC-registered pharmacy #9012878, ensuring reliable supply chains for continuing patients. The prescribing pathway remains identical for both medications, requiring clinical assessment and ongoing monitoring. However, individual insurance coverage may vary between the two options, making cost considerations particularly relevant for long-term treatment planning in the UK private healthcare market.
Making Your Decision With Professional Clinical Support
Both Wegovy and Mounjaro are available from EverydayMeds following appropriate clinical assessment - your prescriber can help determine which option best suits your individual circumstances. Our clinical team evaluates factors including your medical history, previous weight management attempts, lifestyle considerations, and treatment preferences when recommending between these prescription-only medicines. The decision ultimately rests on matching the most appropriate mechanism of action to your specific metabolic profile and weight management objectives. We provide ongoing support throughout your treatment journey, with regular check-ins to monitor progress and adjust dosing as needed. Whether you choose Wegovy's proven GLP-1 pathway or Mounjaro's innovative dual approach, our commitment remains delivering safe, effective weight management solutions backed by clinical excellence and pharmaceutical expertise.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
